Comparing Genetic Testing Models for Hereditary Cancer Syndrome

This study is comparing two ways to offer genetic testing for hereditary cancer syndromes (conditions that increase your risk of cancer and can be passed down in families) in community health centers. Researchers want to see if the "Mainstream Genetic Testing Model" or the "Enhanced Standard of Care Model" is better at getting more people to get tested. You may be able to join if you are an adult aged 25 or older, speak English, and have been identified as potentially needing genetic testing for hereditary breast or colon cancer (like for BRCA or Lynch syndrome). The main goal is to see how many people get genetic testing within two years. The current recruitment status is unclear.

Study design
This study is an interventional trial with a planned enrollment of 80 participants. It uses a randomized design to compare two different approaches to genetic testing.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of the study is measured at 2 years, which suggests a follow-up period of at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05664867

Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC)

Recruiting
NAAges 25+InterventionalPrevention
University of Illinois at Chicago
~80 participants
Updated 2026-01-14 on ClinicalTrials.gov
What's tested:Mainstream Genetic Testing ModelEnhanced Standard of Care Model

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Uptake of genetic testing
Measured over 2 years
Hereditary Cancer Syndrome
1 sites across 1 states
Illinois1

Opens a ready-to-send draft in your own email app — review before sending.

  • Uptake of genetic testing2 years

    compare the uptake of genetic testing among patients in both models of cancer genetic delivery who screen positive on hereditary cancer risk asserssment (HCRA)